A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis—A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial

John E. Edwards,Michael M. Schwartz,Clint S. Schmidt,Jack D. Sobel,Paul Nyirjesy,Florian Schödel,Erica Marchus,Mary Lizakowski,Elizabeth A DeMontigny,Jesse Hoeg,Tuomas Holmberg,M Timothy Cooke,Keila Hoover,Lance Edwards,Mark Jacobs,Steven Sussman,Michael Augenbraun,Michael Drusano,Michael R. Yeaman,Ashraf S. Ibrahim,Scott G. Filler,John P. Hennessey

A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis—A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial

2018

Background Recurrent vulvovaginal candidiasis (RVVC) is a problematic form of mucosal Candida infection, characterized by repeated episodes per year. Candida albicans is the most common cause of RVVC. Currently, there are no immunotherapeutic treatments for RVVC.

Keywords:

Immunology
Dermatology
Vulvovaginal Candidiasis
Medicine
Placebo-controlled study
Recurrent vulvovaginal candidiasis
Randomized controlled trial
Clinical trial
Vaccination
Candida albicans
Placebo
Internal medicine
Fungal vaccine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations